There have been considerable advances in cancer immunotherapy in recent years, these are mainly due to in-depth studies on the programmed cell death protein 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway. The gene discussed is PDCD1; the disease is cancer.